Article
Gilead's Trodelvy extends breast cancer survival by 3.2 months -study
Rating:
0.0
Views:
74
Likes:
1
Library:
1
Gilead Sciences Inc's Trodelvy extended by 3.2 months the survival of patients with advanced stages of a common type of breast cancer, according to data released ahead of a presentation at a European cancer meeting on Friday.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value